HC Wainwright & Co. Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has initiated coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and set a price target of $45.

January 08, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurogene received a Buy rating from HC Wainwright & Co. with a price target of $45, indicating a positive outlook from the analyst.
Analyst ratings, especially initiations of coverage with a Buy rating, can have a significant positive impact on a stock's short-term price as they often lead to increased investor interest and perceived validation of the company's prospects. The announcement of a price target that is substantially higher than the current trading price can further bolster investor sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100